Xencor/$XNCR
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Xencor
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
- Ticker
- $XNCR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 260
- Headquarters
- Pasadena, United States
- Website
- www.xencor.com
Xencor Metrics
BasicAdvanced
$2.2B
-
-$2.18
0.84
-
Price and volume
Market cap
$2.2B
Beta
0.84
52-week high
$33.60
52-week low
$10.38
Average daily volume
1.6M
Financial strength
Current ratio
6.391
Quick ratio
8.923
Long term debt to equity
0.208
Total debt to equity
0.208
Interest coverage (TTM)
-7.98%
Profitability
EBITDA (TTM)
-205.904
Gross margin (TTM)
-143.65%
Net profit margin (TTM)
-155.59%
Operating margin (TTM)
-205.84%
Effective tax rate (TTM)
-1.54%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
-16.83%
Return on equity (TTM)
-29.07%
Valuation
Price to revenue (TTM)
21.314
Price to book
4.4
Price to tangible book (TTM)
4.46
Price to free cash flow (TTM)
-10.742
Free cash flow yield (TTM)
-9.31%
Free cash flow per share (TTM)
-2.776
Growth
Revenue change (TTM)
-28.56%
Earnings per share change (TTM)
-9.27%
3-year revenue growth (CAGR)
-2.54%
10-year revenue growth (CAGR)
0.64%
3-year earnings per share growth (CAGR)
0.58%
10-year earnings per share growth (CAGR)
8.75%
What the Analysts think about Xencor
Analyst ratings (Buy, Hold, Sell) for Xencor stock.
Analyst projections of the future price of Xencor stock.
Bulls say / Bears say
At the proposed dose, XmAb819 produced a 45.5% confirmed response rate in advanced kidney cancer, with an estimated 82% of patients progression-free at six months. The responses came in heavily pre-treated patients, making the early signal encouraging. (BusinessWire)
Xencor has selected a dose for further development and plans a global randomised study of XmAb819 against tivozanib, with FDA discussions on a possible accelerated-approval route due in the first half of 2027. This gives the programme a defined path towards testing whether the early results can translate into approval. (BusinessWire)
Xencor has other potential catalysts beyond XmAb819: its ulcerative-colitis drug XmAb942 is in Phase 2b, with an interim analysis expected around year-end 2026, while partner Zenas filed for approval of obexelimab and triggered a $10 million milestone. This gives investors clinical and partner-led sources of potential progress. (Xencor)
The 45.5% response rate for XmAb819 is based on just 11 patients at the selected dose, with no randomised comparison and only six months of median follow-up. The small sample leaves substantial uncertainty about how well the result will hold up in a larger trial. (Seeking Alpha, BusinessWire)
XmAb819 also carries a significant safety burden: 72.1% of patients in its combined expansion cohorts had a related Grade 3 or worse adverse event, commonly liver-enzyme elevations or rash. These effects could complicate treatment and development even though few patients stopped treatment because of them. (BusinessWire)
Data summarised monthly by Lightyear AI. Last updated on 26 Oct 2026.
Xencor Financial Performance
Revenues and expenses
Xencor Earnings Performance
Company profitability
Upcoming events
No upcoming events
Xencor News
AllArticlesVideos
Xencor Picks Phase 3 Dose After XmAb819 Shows 45.5% Response Rate in Kidney Cancer
MarketBeat6 days ago
Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors
Business Wire1 week ago
Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Business Wire2 weeks ago
Funds containing Xencor
Fund name | Fund size | $XNCR weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.14% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.14% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.11% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.11% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.07% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.